The Effects of Aging and Estrogen on the Pituitary

• ClinicalTrials.gov Identifier: NCT00386022
• Recruitment Status: Unknown
• First Posted: October 11, 2006
• Results First Posted: April 13, 2017
• Last Update Posted: April 13, 2017
• Sponsor: Massachusetts General Hospital
• Collaborator: National Institute on Aging (NIA)
• Information provided by (Responsible Party): Janet E. Hall, MD, Massachusetts General Hospital

Tracking Information

• First Submitted Date: October 6, 2006
• First Posted Date: October 11, 2006
• Results First Submitted Date: May 22, 2014
• Results First Posted Date: April 13, 2017
• Last Update Posted Date: April 13, 2017
• Study Start Date: January 2002
• Actual Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: April 12, 2017)

• Pituitary Response to GnRH [ Time Frame: Peak hormone level within 2 hours post GnRH doses ]
  Baseline LH and FSH responses to each of 4 GnRH doses - peak to nadir amplitude expressed as percent (%) change from nadir
• Effect of Estrogen on Pituitary Response to GnRH [ Time Frame: Peak hormone level within 2 hours post GnRH doses ]
  LH and FSH responses to each of 4 GnRH doses, expressed as change in amplitude [amp] from peak to nadir between plus estrogen and baseline conditions

• Original Primary Outcome Measures (submitted: October 6, 2006): pituitary response after GnRH stimulation; LH, FSH and FAS, the peak amplitude, and area under the curve for each GnRH dose per study group
• Current Secondary Outcome Measures: Not Provided
• Original Secondary Outcome Measures: Not Provided
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: The Effects of Aging and Estrogen on the Pituitary
• Official Title: The Effect of Aging on the Isolated Pituitary Response to Gonadotropin Releasing Hormone at Baseline and With Low Dose Estrogen Administration
• Brief Summary: The purpose of this study is to study the effects of aging and estrogen on the brain. Specifically, this study will examine how the hypothalamus signals the pituitary gland to secrete reproductive hormones and how that changes with aging.

Detailed Description

Although it is clear that loss of ovarian function plays a major role in the menopause in women, there is evidence from animal studies that primary age-related hypothalamic and pituitary changes may also contribute to reproductive aging. Complete cessation of ovarian function results in the loss of negative feedback of ovarian steroids and inhibin on the hypothalamic and pituitary components of the reproductive axis. An increase in serum levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) occurs in postmenopausal women with removal of negative ovarian feedback. However, levels of LH and FSH after menopause decline steadily as a function of age in most though not all studies.

The current study is designed to determine: 1) whether negative feedback on LH and FSH occurs at the pituitary; and 2) whether there is an effect of aging on estrogen negative feedback at the pituitary. Younger and older postmenopausal women underwent a baseline study and a second identical study after a month of low dose estrogen replacement. The study protocol consisted of the following: 1) administration of a GnRH antagonist (Nal-Glu at 150 mg/kg that blocks endogenous GnRH so that the dose and interval of pituitary exposure to GnRH are precisely controlled; 2) beginning 8 hours following GnRH antagonist administration (at a time when LH had reached its nadir following GnRH receptor blockade), administration of 4 graded doses of GnRH (25, 75, 250 and 750 ng/kg every 2 hours with 2 hours of blood draws following each dose). Blood was sampled every 30 min for 4 hours before antagonist administration, every 30 min for the following 7 hours and then every 10 min until the completion of the study.

• Study Type: Interventional
• Study Phase: Phase 2; Phase 3

Study Design

Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:

The study will is considered sequential as participants were studied at baseline and after one month of low-dose estrogen. Randomization refers to randomization of the order of doses of GnRH between participants.

Masking: None (Open Label)
Primary Purpose: Other

• Condition: Healthy

Intervention

• Drug: GnRH
  GnRH doses of 25, 75, 250 and 750 ng/kg will be given IV every 4 hr at baseline and after transdermal estradiol
  Other Names:

  • gonadotropin-releasing hormone
  • Factryl
• Drug: NAL-GLU GnRH antagonist
  A single subcutaneous injection of the NAL-GLU GnRH antagonist at a dose of 150 mcg/kg before and after transdermal estradiol
  Other Name: GnRH antagonist
• Drug: Estrogen patch
  transdermal estrogen patches 0.05mg/day, changing the patch every 86 hr in second part of sequential study
  Other Names:

  • Climara
  • Estraderm

Study Arms

• Experimental: Young postmenopausal women
  intervention: graded doses of GnRH following NAL-GLU GnRH antagonist administration with or without transdermal estrogen patch
  Interventions:

  • Drug: GnRH
  • Drug: NAL-GLU GnRH antagonist
  • Drug: Estrogen patch
• Experimental: Older postmenopausal women
  intervention: graded doses of GnRH following NAL-GLU GnRH antagonist administration with or without transdermal estrogen patch
  Interventions:

  • Drug: GnRH
  • Drug: NAL-GLU GnRH antagonist
  • Drug: Estrogen patch

Publications *

• Shaw ND, Histed SN, Srouji SS, Yang J, Lee H, Hall JE. Estrogen negative feedback on gonadotropin secretion: evidence for a direct pituitary effect in women. J Clin Endocrinol Metab. 2010 Apr;95(4):1955-61. doi: 10.1210/jc.2009-2108. Epub 2010 Feb 4.
• Shaw ND, Srouji SS, Histed SN, McCurnin KE, Hall JE. Aging attenuates the pituitary response to gonadotropin-releasing hormone. J Clin Endocrinol Metab. 2009 Sep;94(9):3259-64. doi: 10.1210/jc.2009-0526. Epub 2009 Jun 23.

Recruitment Information

• Recruitment Status: Unknown status
• Actual Enrollment (submitted: April 12, 2017): 19
• Original Enrollment (submitted: October 6, 2006): 40
• Estimated Study Completion Date: January 2018
• Actual Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• 45-55 or 70-80 years old
• History of natural menopause defined by the absence of menses for at least 12 months (or history of surgical menopause defined as bilateral oophorectomy) and a FSH level >26 IU/L
• On no hormonal medication or herbal supplements and/or over the counter menopause therapy for a minimum of 2 months prior to study
• Normal thyroid stimulating hormone, prolactin, factor V Leiden, and complete blood count - Normal blood urea nitrogen and creatinine (< 2 times the upper limit of normal)
• basal metabolic index ≤ 30
• Non-smokers or smoke less than 10 cigarettes/day

Exclusion Criteria:

• Absolute contraindications to the use of physiologic replacement doses of estrogen, including a negative screening mammogram within the past 24 months
• History of coronary artery disease
• On medications thought to act centrally on the GnRH pulse generator
• Past history of hypersensitivity or allergy to narcotics, vancomycin, muscle relaxants, aspirin, and/or anaphylactic reaction(s) to other drugs
• Prior history of breast cancer and/or blood clots

Sex/Gender

• Sexes Eligible for Study: Female

• Ages: 45 Years to 80 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT00386022
• Other Study ID Numbers: 2000-P-002498; R01AG013241 ( U.S. NIH Grant/Contract )
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided

IPD Sharing Statement

• Plan to Share IPD: Yes
• Plan Description: Coded data with identifying information can be requested by contacting the PI.

• Responsible Party: Janet E. Hall, MD, Massachusetts General Hospital
• Study Sponsor: Massachusetts General Hospital
• Collaborators: National Institute on Aging (NIA)

Investigators

• Principal Investigator: Janet E Hall, M.D.; Massachusetts General Hospital

• PRS Account: Massachusetts General Hospital
• Verification Date: April 2017